Hospital
Kaleida Health
Kaleida Health was paid $5.40M by Medicaid between Jan 2019 and Dec 2024, across 77 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoKALEIDA HEALTH
NORTH TONAWANDA, NY 14120
NORTH TONAWANDA, NY 14120
33aNPI1104956358assigned 03/06/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.40M
24GClaims79,222
24DCodes billed77
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#91 of 231
Median peer was paid$561K
This provider vs. median9.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 729 | $40K | |
| 2020 | 2,351 | $164K | |
| 2021 | 12,495 | $809K | |
| 2022 | 20,478 | $1.43M | |
| 2023 | 23,792 | $1.61M | |
| 2024incomplete | 19,377 | $1.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 8,109 | 7,780 | $1.57M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 5,825 | 5,557 | $997K |
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 3,001 | 2,766 | $804K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.3% | 1,875 | 1,819 | $341K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.9% | 1,746 | 1,694 | $320K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.4% | 796 | 791 | $291K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 555 | 553 | $199K |
| 80053 | Comprehensive metabolic panel | 3.3% | 8,063 | 7,602 | $181K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.2% | 567 | 560 | $119K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 307 | 304 | $113K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.4% | 1,244 | 1,230 | $73K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 1,095 | 395 | $66K |
65 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,459 | $37K |
| 87631 | <1% | 641 | $35K | |
| 82803 | <1% | 728 | $24K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 550 | $23K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 776 | $23K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,169 | $17K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,659 | $14K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 15 | $14K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 430 | $12K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,251 | $12K |
| 80061 | Lipid panel | <1% | 1,674 | $11K |
| 97010 | <1% | 768 | $10K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 50 | $10K |
| 81025 | <1% | 2,728 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 228 | $9K |
| 82607 | <1% | 670 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 787 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,055 | $7K |
| 84439 | <1% | 758 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 239 | $5K |
| 82746 | <1% | 364 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 271 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 176 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,117 | $3K |
| 81001 | <1% | 605 | $2K | |
| 80047 | <1% | 74 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,750 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 17 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 907 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 491 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,120 | $794.14 |
| 81003 | <1% | 2,921 | $654.82 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 129 | $623.06 |
| 86803 | <1% | 166 | $579.31 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,693 | $547.80 |
| 71045 | Radiologic examination, chest; single view | <1% | 998 | $477.84 |
| 90715 | <1% | 12 | $443.80 | |
| 82550 | <1% | 66 | $325.35 | |
| 85027 | <1% | 81 | $280.84 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 25 | $238.49 |
| 84153 | <1% | 12 | $220.81 | |
| 73564 | <1% | 56 | $217.20 | |
| 82570 | <1% | 39 | $209.67 | |
| 73610 | <1% | 72 | $206.06 | |
| 84484 | <1% | 1,335 | $189.53 | |
| 73630 | <1% | 98 | $153.95 | |
| 82043 | <1% | 24 | $123.35 | |
| 83540 | <1% | 24 | $120.85 | |
| 83735 | <1% | 27 | $110.54 | |
| 72110 | <1% | 12 | $102.00 | |
| 73130 | <1% | 28 | $93.19 | |
| 85651 | <1% | 24 | $44.00 | |
| 83690 | <1% | 68 | $41.89 | |
| 83605 | <1% | 357 | $31.98 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,074 | $17.49 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,425 | $7.65 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 111 | $6.49 |
| 85014 | <1% | 58 | $2.12 | |
| 83721 | 0% | 25 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 99 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 12 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 101 | $0.00 |
| 96376 | 0% | 141 | $0.00 | |
| 87070 | 0% | 173 | $0.00 | |
| 87430 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCROREY, ANGELA (AR MANAGER)
Parent organizationKALEIDA HEALTH
| Provider | Location | Paid |
|---|---|---|
| Kaleida Health | Buffalo, NY | $80.65M |
| Kaleida Health | Buffalo, NY | $30.80M |
| Kaleida Health | Williamsville, NY | $11.67M |
| Kaleida Health | Buffalo, NY | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.